A new cure model that corrects for increased risk of non-cancer death: analysis of reliability and robustness, and application to real-life data

Autor: Laura Botta, Juste Goungounga, Riccardo Capocaccia, Gaelle Romain, Marc Colonna, Gemma Gatta, Olayidé Boussari, Valérie Jooste

Publikováno v: BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-19 (2023)

Abstract Background Non-cancer mortality in cancer patients may be higher than overall mortality in the general population due to a combination of factors, such as long-term adverse effects of treatments, and genetic, environmental or lifestyle-relat

Externí odkaz: https://doaj.org/article/d57db8ce6b754f40848676e045e593c7

Dry season determinants of malaria disease and net use in Benin, West Africa.

Autor: Nicolas Moiroux, Olayidé Boussari, Armel Djènontin, Georgia Damien, Gilles Cottrell, Marie-Claire Henry, Hélène Guis, Vincent Corbel

Publikováno v: PLoS ONE, Vol 7, Iss 1, p e30558 (2012)

BackgroundTo achieve malaria eradication, control efforts have to be sustained even when the incidence of malaria cases becomes low during the dry season. In this work, malaria incidence and its determinants including bed net use were investigated in

Externí odkaz: https://doaj.org/article/403361c2462e410fbd51066e0b955018

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials

Autor: Clémence Breton, Jean-Baptiste Bachet, Jaafar Bennouna, Sylvain Manfredi, Jean-Louis Legoux, Aimery de Gramont, Karine Le Malicot, Thomas Aparicio, Thierry Lecomte, Olivier Bouché, Michel Ducreux, Olayidé Boussari, Julien Taieb, Jean-Marc Gornet

Publikováno v: European Journal of Cancer. 153:40-50

Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC).Individual patient data of 2190 patients enroll

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141b76f62d34e2a5fb83924e3ebdb6c9
https://doi.org/10.1016/j.ejca.2021.04.040

Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery

Autor: Geneviève Belleannée, Laurence Chiche, Christophe Laurent, N. Leduc, C. Pouypoudat, Véronique Vendrely, R. Trouette, Etienne Buscail, Karine Le Malicot, Denis Smith, Olayidé Boussari, Jean-Frédéric Blanc, Bruno Lapuyade, Sarah Adgié, Eric Terrebonne, Mario Terlizzi

Publikováno v: Acta oncologica (Stockholm, Sweden). 60(9)

Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US).Between 2010 and 2017 pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf84147409b61c0833d7734ac3b9f9c
https://pubmed.ncbi.nlm.nih.gov/34197269

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

Autor: Michal Abrahamowicz, Adrien Guilloteau, Karine Le Malicot, Olayidé Boussari, Thomas Aparicio, Christine Binquet, Valérie Jooste, Catherine Quantin

Publikováno v: BMC Medical Research Methodology
BMC Medical Research Methodology, BioMed Central, 2021, 21 (1), pp.14. ⟨10.1186/s12874-020-01202-9⟩
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-10 (2021)

Background As cancer treatment, biotherapies can be as effective as chemotherapy while reducing the risk of secondary effects, so that they can be taken over longer periods than conventional chemotherapy. Thus, some trials aimed at assessing the bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff85ece06d3bd7d4774262fa4399f54
https://www.hal.inserm.fr/inserm-03314999